Cumberland Pharmaceuticals Inc. (CPIX)
NASDAQ: CPIX · Real-Time Price · USD
5.31
-0.64 (-10.76%)
At close: Feb 21, 2025, 4:00 PM
5.21
-0.10 (-1.86%)
After-hours: Feb 21, 2025, 6:02 PM EST
CPIX Revenue
Cumberland Pharmaceuticals had revenue of $9.09M in the quarter ending September 30, 2024, a decrease of -9.92%. This brings the company's revenue in the last twelve months to $36.79M, down -6.45% year-over-year. In the year 2023, Cumberland Pharmaceuticals had annual revenue of $39.55M, down -5.85%.
Revenue (ttm)
$36.79M
Revenue Growth
-6.45%
P/S Ratio
2.04
Revenue / Employee
$404,236
Employees
91
Market Cap
74.56M
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2023 | 39.55M | -2.46M | -5.85% |
Dec 31, 2022 | 42.01M | 6.03M | 16.75% |
Dec 31, 2021 | 35.99M | -1.46M | -3.89% |
Dec 31, 2020 | 37.44M | 3.05M | 8.88% |
Dec 31, 2019 | 34.39M | 5.04M | 17.19% |
Dec 31, 2018 | Pro | Pro | Pro |
Dec 31, 2017 | Pro | Pro | Pro |
Dec 31, 2016 | Pro | Pro | Pro |
Dec 31, 2015 | Pro | Pro | Pro |
Dec 31, 2014 | Pro | Pro | Pro |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
UnitedHealth Group | 400.28B |
Johnson & Johnson | 88.82B |
Merck & Co. | 64.17B |
AbbVie | 56.33B |
AstraZeneca | 54.07B |
Novartis AG | 51.72B |
Eli Lilly and Company | 45.04B |
Thermo Fisher Scientific | 42.88B |
CPIX News
- 5 days ago - VIBATIV® RECEIVES MARKETING APPROVAL IN CHINA - PRNewsWire
- 18 days ago - Cumberland Pharmaceuticals' Duchenne Candidate Shows Improved Heart Function In Patients With Associated Heart Disease - Benzinga
- 19 days ago - Cumberland Pharmaceuticals Announces Breakthrough Results from the Phase 2 FIGHT DMD Trial in Duchenne Muscular Dystrophy Heart Disease - PRNewsWire
- 2 months ago - Why Is Cumberland Pharmaceuticals Stock Trading Over 100% on Tuesday? - Benzinga
- 2 months ago - FDA APPROVES ACETADOTE® sNDA - PRNewsWire
- 3 months ago - Cumberland Pharmaceuticals Inc. (CPIX) Q3 2024 Earnings Call Transcript - Seeking Alpha
- 3 months ago - Cumberland Pharmaceuticals Reports Third Quarter 2024 Financial Results and Company Update - PRNewsWire
- 3 months ago - CUMBERLAND PHARMACEUTICALS RECEIVES FDA ORPHAN DRUG AND RARE PEDIATRIC DISEASE DESIGNATIONS FOR NEW TREATMENT OF DUCHENNE MUSCULAR DYSTROPHY - PRNewsWire